•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Minerva S.A. (MRVSY) Q3 2026 Earnings Call Transcript
Minerva Foods Reports Net Revenue of R$56.2 Billion in 12 Months
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
Minerva (OTCMKTS:MRVSY) Stock Price Breaks Below Two Hundred Day Moving Average – Should You Sell?
Minerva S.A. (OTCMKTS:MRVSY) Short Interest Update
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 57,2 BILLION FOR THE PAST 12 MONTHS
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva Launches AI Platform for Consumer Marketing with $20M from The General Partnership, 8VC, Lingotto Innovation, Topology Ventures and NBA Investments, Alongside OpenAI Collaboration
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva S.A. (MRVSY) Q1 2026 Earnings Call Transcript
MINERVA FOODS REPORTS R$ 13.4 BILLION IN NET REVENUE IN THE FIRST QUARTER OF 2026
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva S.A. (MRVSY) Q4 2025 Earnings Call Transcript
Already premium?